Keck School Faculty

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results Nat Med. 2023 Apr 03. . View in PubMed

Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma Int J Radiat Oncol Biol Phys. 2023 Apr 01; 115(5):1115-1128. . View in PubMed

Congenital central hypoventilation syndrome without hypoventilation: is it congenital central hypoventilation syndrome? J Clin Sleep Med. 2023 Feb 17.. View in PubMed

Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus Pediatr Blood Cancer. 2023 05; 70(5):e30217. . View in PubMed

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma Nat Commun. 2023 05 05; 14(1):2601. . View in PubMed

Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy Pediatr Blood Cancer. 2022 09; 69(9):e29719. . View in PubMed

Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures Radiat Res. 2022 02 01; 197(2):101-112. . View in PubMed

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium J Clin Oncol. 2021 11 01; 39(31):3506-3514. . View in PubMed

Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer J Pain Symptom Manage. 2020 10; 60(4):782-789. . View in PubMed

Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: A case series and review of the literature Pediatr Blood Cancer. 2020 08; 67(8):e28236. . View in PubMed

The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors J Surg Res. 2020 05; 249:8-12. . View in PubMed

Unrealistic parental expectations for cure in poor-prognosis childhood cancer Cancer. 2020 01 15; 126(2):416-424. . View in PubMed

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531 J Clin Oncol. 2019 12 01; 37(34):3243-3255. . View in PubMed

Rare MYC-amplified Neuroblastoma With Large Cell Histology Pediatr Dev Pathol. 2018 Sep-Oct; 21(5):461-466. . View in PubMed

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial Pediatr Blood Cancer. 2018 07; 65(7):e27023. . View in PubMed

Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v10) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 05; 65(5):e26940. . View in PubMed

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma Clin Cancer Res. 2018 12 15; 24(24):6142-6149. . View in PubMed

Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors Bone Marrow Transplant. 2017 Nov; 52(11):1543-1548. . View in PubMed

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. . View in PubMed

The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy J Pediatr Oncol Nurs. 2017 May/Jun; 34(3):160-172. . View in PubMed

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial J Clin Oncol. 2016 Apr 20; 34(12):1368-75. . View in PubMed

Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG) Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. . View in PubMed

Comparative pharmacokinetics, safety, and tolerability of two sources of ch1418 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. . View in PubMed

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine Eur J Cancer. 2016 10; 66:144-52. . View in PubMed

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma Pediatr Blood Cancer. 2016 08; 63(8):1349-56. . View in PubMed

The clinical management and outcomes of cervical neuroblastic tumors J Surg Res. 2016 07; 204(1):109-13. . View in PubMed

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. . View in PubMed

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastomaA new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. . View in PubMed

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31. . View in PubMed

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study BMC Res Notes. 2014 Apr 23; 7:256. . View in PubMed

Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors Pediatr Blood Cancer. 2013 Dec; 60(12):2012-7. . View in PubMed

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. . View in PubMed

Forearm skeletal muscle neuroblastoma in a child: a rare primary location J Pediatr Hematol Oncol. 2013 Jan; 35(1):61-3. . View in PubMed

The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma Pediatr Blood Cancer. 2012 May; 58(5):675-81. . View in PubMed

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial Clin Cancer Res. 2012 May 01; 18(9):2679-86. . View in PubMed

A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. . View in PubMed

Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. . View in PubMed

Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex Pediatr Blood Cancer. 2010 Jan; 54(1):170-2. . View in PubMed

High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome Cancer. 2009 Jul 01; 115(13):2956-63. . View in PubMed

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors Bone Marrow Transplant. 2008 Jan; 41(2):167-72. . View in PubMed

Predictors of outcome in children with Langerhans cell histiocytosis Pediatr Blood Cancer. 2005 Jul; 45(1):37-42. . View in PubMed